Climb Career Mountains But Return Safe

One of the biggest myths for career seekers is their belief that it is an easy linear slope. This is the reason many struggle with some career plateaus. Some are surprised with sudden career cliffs; others are scared of the stiff heights of career hills. Career building in today’s world of turbulence and opportunity is more like adventure sport. Exhilarating and scary, possibly at the same step. You need to be spirited and yet you must avoid missteps. That is how new age careers will need to be – a series of experiences, the ups and the downs, the moments of high and the moments of low. The one who will understand this, prepare for this and, most of all, goes ahead to do it will be the one who will script a successful career.

Career adrenaline   

Anyone who dreams of a career must have the energy and the passion to nurture one. Just having an education qualification or some prior experience is not it. It is the hunger to excel, to take chances, to make every indifferent opportunity a trailblazing experience. It is about infinite optimism to win. It is the tenacity to persevere. You need to have the career adrenaline.

Nutritional supplement
The journey is exacting. There are phases of stretch and stress – physical, mental and emotional. You get exposed to negative influences and infected with the virus of cynicism. To ensure you stay strong and healthy on this exciting adventure you need to supplement your diet with additional nutrition. Special skills, rotation to different experiences, coaching, feedback, stretch projects, peer feedback – these help add that extra strength to a fundamentally good mind and body. They keep you agile, alert and well-sinewed.

Many of us strain ourselves, even enjoying that style, to perform, stretch and deliver always. While this is the adrenaline pumping and is wonderful, it is equally important to slow down at times. Take a break. A sabbatical. It is a phase to pause and reflect. Ask some fundamental questions about our purpose of life and doing. Reinforce beliefs. Repudiate myths and illusions. This is a time of rest and recovery. It may seem to be a plateau but has ahuge value for us.

The climber’s club 
Careers have their highs and lows. There are giant boulders intimidating us. There are the loose rocks that can also become precipitous. You need to tread carefully -sometimes trusting your own instinct, at other times, connected and supported by fellow rock climbers. There is the need to give and take. It is foolish to assume, we can scale all the peaks all alone. Choosing the right set of fellow climbers is key. Each brings a strength that helps us move forward, safely but surely. We need to select right and trust right. Enabled by individual capability and powered by the safety norms of the collective. The instinct to trust, collaborate and encourage each other makes for successful climbing. This could be the difference to reaching the peak or falling to depths.

Celebrate the exhilaration 
The peak is not always the most exciting moment of the expedition. It is more a metaphor for closure. There are many moments along the way that may be more demanding, exciting and fulfilling. We must learn to celebrate these exciting moments as much. Otherwise, waiting to celebrate only at the peak will make the trek up tedious and, possibly, uninspiring.

The climb down and after 
Once you are up on the point that you dreamt about, soak in your achievement. And then open your eyes and look down. You also have to get back from where you started. Success can leave you isolated and lonely. Perched high above, with no one to celebrate with, can ironically be depressive. The ability and willingness to carefully climb down from this high is not one that every peak conqueror has. This is equally treacherous and threatening. Sometimes going up may seem easier than going down. This is where our true character and prowess may be tested.

This article originally appeared in Economic Times

For more such blogs follow us on Twitter, Facebook, LinkedIn.

Cipla Q3 FY18 Results Reflect Continuously Improving Quality Of Earnings Backed By Strong Momentum Across Key Regions

Press Release

Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended December 31, 2017. The Company reported quarterly revenues of Rs 3,914 crores, a growth of 7% on a year-on-year basis, with EBITDA at 20.9%, growing 21% on a year-on-year basis. EBITDA margins have been improving continuously driven by cost optimization across all spend lines despite R&D getting stepped up to 7.6% of sales during the quarter. When adjusted for the one-offs during the quarter, the Profit After Tax rose by ~25% on a year-on-year basis. The Company reported healthy growth across businesses in India, South Africa, API, Europe and Sub-Saharan Africa markets.

“This has been one of our better quarters. Key performance metrics look healthy and are inline
with the internal targets we set for ourselves. We are stepping up our investments in R&D
which has resulted in approvals for differentiated products in the US”
– Umang Vohra
MD and Global CEO, Cipla Ltd

Download the PDF.

For more such blogs follow us on TwitterFacebookLinkedIn.

Programme On Nutritious Food Organised By Cipla

Samala Hema, Seethaphalmandi Corporator attended the programme about nutritious food organised by Cipla industries at Jyothi Model High School, here on Wednesday. As a part of the programme, experts from the health industry held a session to explain parents’ about child health and immunity.

The corporator too encouraged children and the parents to adopt a hygienic and healthy lifestyle to protect young lives. Later, the corporator along with officials of the GHMC and senior TRS leaders comprising Laxman Rao, ward member of the constituency interacted with the residents of Beedal Basthi as a part of the Basthi Baata programme to know their problems.

This article originally appeared in The Hans India.

For more such blogs follow us on TwitterFacebookLinkedIn.

Cipla Receives Final Approval for a Generic Version of Gilead’s Viread®

Press Release

Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Gilead Sciences’ Viread® Tablets, 300mg.

Cipla’s Tenofovir Disoproxil Fumarate Tablets, 300mg, are AB-rated generic equivalents of Gilead Sciences’ Viread® Tablets, 300mg, and are indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults and paediatric patients 12 years of age and older. Cipla is excited to add this important antiretroviral product to its growing portfolio of ARVs in the U.S.

The product will be available for commercial shipment in the U.S. immediately. Viread® Tablets,
300mg, had U.S. sales of approximately $725M for the 12-month period ending November 2017,
as reported by IMS Health.

For more such blogs follow us on TwitterFacebookLinkedIn.

India’s Cancer Cases Far Lower Than Those In The West, Yet Death Rate Higher

India’s cancer graphs tell two distinct stories. The first holds out hope as India’s cancer incidence is far lower than developed nations such as Denmark and the US. If cancer strikes over 300 out of every 100,000 population in Denmark, the corresponding number in India hovers around 80. But the second Indian cancer story is worrisome: cancer manages to get the upper hand in almost 70% of cases in India. A study in the medical journal, The Lancet, in 2014 indicated only 30% of India’s cancer patients survive for over five years.

So while India has lower cancer rates than many other countries, it has a high death rate. Check the World Health Organisation’s Globocan 2012 report’s analysis for breast cancer: only 1 out every 5 or 6 women newly diagnosed with breast cancer died in the US, but corresponding figures in India stood at 1out of every 2 patients.

Experts said early detection could go a long way in reducing the high death rate caused due to illiteracy, fear and taboos. “In India, almost 50% of all cancers are seen in late stages. This is the reason our death rate is higher than western countries,” said senior medical oncologist Shona Nag.

Maximum cancer patients succumb to lung, head and neck and breast cancers. “We lose almost 80% of all patients detected with lung cancer. The death rate due to breast cancer world over is 20%, but we lose over 50% of our breast cancer patients,” Nag said.

Almost 80% of cervical cancer patients are diagnosed in stage 3-4 in India, but the West has almost eradicated this cancer due to regular pap smear tests. Given India’s population, it is impossible to scan everybody. “Self-breast exams and clinical exams involving community workers or ancillary health professionals are hence crucial,” she added.

Lack of awareness is the main cause for late detection. “In the western world, the culture is openness and they are more aware. Though we have facilities, we cannot reach out to such a huge population. Almost all cancers are detected at late stage in India mainly because of lack of awareness and social stigma,” said medical oncologist Anantbhushan Ranade.

Cancer surgeon Anupama Mane said, “We have women with 10cm lumps who come to us late because the lump didn’t hurt or cause pain so they did not think a check was needed.” Moreover, men don’t discuss women’s health. “So a blood stain or excessive bleeding is dismissed and not taken up as cause for worry,” Mane said. Early detection is key to reduce mortality. “It is important to diagnose cancer early because then you have a chance at curing it. The spread and extent of it make it harder to control,” said oncosurgeon Snita Sinukumar. Lack of a dedicated health care system is one of the big reasons for higher deaths. “Just like Aadhar, we need to make it compulsory to invest in one’s own healthcare,” Sinukumar added.

This article originally appeared on The Times of India

For more such blogs follow us on Twitter, Facebook, LinkedIn.